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Abstract 
 
One of the major obstacles facing the ﬁeld of structural biology in the postgenomic era is 
the inherent difficulty of solving the structure of membrane proteins under native 
conditions. Membrane proteins share a common property; part of their structure is 
embedded in the lipid bilayer. This feature makes them attractive drug targets, which 
requires a detailed knowledge of the secondary structure of their transmembrane domain. 
Both crystallography and NMR still encounter difficulties in handling membrane proteins, 
so there is an urgent need for new biophysical methods and new insights in the biophysics 
of membrane proteins to solve the secondary structure of such proteins. 
The outbreak of the severe acute respiratory syndrome (SARS) virus, July 2003, has 
presented a formidable challenge for the scientific community. As part of that  effort, we 
decided to study the high resolution backbone structure of E transmembrane proteins of the 
SARS coronavirus, by Attenuated Total Internal Reﬂection (ATR) FTIR of eighteen of 
isotopically labeled sites with (13C=18O) of the synthesized sequence for the SARS 
coronavirus E protein transmembrane domain. ATR-FTIR spectroscopy is a well-
established method for generating precise structural information on isotopically labeled 
membrane proteins embedded in a lipid bilayer. We used the new biophysical method site 
specific infrared dichroism (SSID), to investigate the structure and orientation of 
transmembrane α-helical bundles.  
We postulate in this work that the E protein of SARS CoV is α-helix, and it has 26 residues 
embedded in the lipid bilayer, and the SARS CoV E protein is not a regular helix, but it 
adopts a unique transmembrane helical hairpin model, and the E protein has two possible 
kinks at residue No. 26 and 31 Phe and Leu respectively within the lipid bilayer, which is 
reported for the first time in this thesis. And it also has a possible kink in residue No 15 too. 
All the results were confirmed experimentally.  
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 الملخص بالعربيه
 
 
إٌدبد الوبٌى الخبص للبزّحٌٍبث الوْخْدة  )ygoloib larutcurts( هي العْائك الخً حْاخَ البٍْلْخٍب البٌبئٍَ
.   فً الأغشٍَ ّالذي ٌحبوً ّخْدُب فً بٍئخِب الطبٍعٍت ، ألا ًُّ طبمخً الذُْى الوىًْت للأغشٍَ فً الخلاٌب
البزّحٌٍبث الوْخْدة فً الأغشٍَ  حىْى هغزّست بٍي طبمخً الذُْى، الىبرُت للوبء، ُّذٍ الوٍشة خذبج العذٌذ 
هي علوبء حصٌٍع الادٌَّ، ّلىي لخصوٍن ُذٍ الادٌَّ ٌُبله حبخَ هبسَ إلى هعزفَ هعلْهبث عي الوبٌى 
. الثبًْي لِذا الدشء هي البزّحٍي الوْخْد داخل طبمخً الذُْى، هي ًبحٍت الوبٌى ّ ّخِخَ داخل الغشبء
الطزٌمخبى الوعزّفخبى حخى ألاى لحل الوبٌى الثبًْي للبزّحٌٍبث الوْخْدة فً الاغشٍَ ُوب طزٌمَ الزًٍي 
، ّلىي حخى ُذٍ  )yhpargollatsyrc(ّطزٌمَ الخصٌْز السًٌٍ البلْري  )RMN(الوغٌبطٍسً الٌّْي 
اللحظت ُذٍ الطزق حعبًً هي صعْببث خوت فً الخعبهل هع البزّحٌٍبث الوْخْدة فً الأغشَ ّ حل هبٌبُب، 
ّلذله ٌُبله حبخَ هبسَ إلى اسخخذام طزٌمَ بٍْفٍشٌبئٍَ خذٌذٍ لذراست البزّحٌٍبث، ّ خبصت الوبٌى الثبًْي 
 .للبزّحٌٍبث الوْخْدة ببلأغشٍَ
  لذ وبى لَ حأثٍز وبٍز على الودخوعبث ّ الشعْة، 3002فً ٌْلٍْ عبم   )SRAS(إى اًخشبر هزض السبرس 
فمذ أصبح ٌُبن ححذ وبٍز ببلٌسبت للعلوبء لحل ُذٍ الوشىلت، ّ ووسبُوت هٌب لزرًب المٍبم بذراست هفصلَ ّدلٍمَ 
) nietorp )E( polevnE(لأحذ البزّحٌٍبث الغشبئٍَ  الوِوت  لفٍزّص السبرص، الوسوى البزّحٍي الوعطفً  
الاًعىبص الذاخلً الىلً الوُْي ببسخخذام ححٌْلاث ( )RITF-RTAِ(، ّلذ اسخخذهٌب طزٌمَ خذٌذٍ حسوى 
للأحوبض   )O81=C31(،  ّ فً ُذٍ الطزٌمَ ًسخخذم دلائل هعذلت الٌظبئز )فْرٌٍز للأشعت ححج الحوزاء
. الأهٌٍٍَ داخل الببخٍذ الوزاد دراسخَ ّالذي ًمْم ببٌبئَ 
ُذٍ الطزٌمَ حعطً هعلْهبث وثٍزة ّدلٍمَ عي الوبٌى الثٌبئً  للبزّحٌٍبث  الوْخْدة فً الأغشٍَ ّ الوغوْست 
. فً الطزق السببمت  ُْ فً طبمخً الذُي، ّلا ححخبج إلى ووٍبث وبٍزٍ هي البزّحٌٍبث أّ إلى ّلج وبٍز ووب 
الخبص بفٍزّص السبرص ُْ عببرة عي بزّحٍي لْلبً  فزٌذ  )nietorp E(حن الخأوٍذ فى ُذا البحث على أى 
هي ًْعَ ، ٌْخذ هٌَ سج ّعشزّى حبهط أهًٌٍ هغزّسٍي داخل الغشبء فً طبمخً الذُْى، ُّْ عببرة عي 
ّول الٌخبئح حن حأوٍذُب بخدبرة .  بزّحٍي  لْلبً غٍز اعخٍبدي فٍَ اًحٌبئٍي داخل الغشبء فً الطبمخٍي الذٌٍُخٍي
                                   ..عولٍت
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CHAPTER I 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  2 
1.1. The SARS Coronavirus 
 
     The coronaviruses (order Nidovirales, family Coronaviridae, genus Coronavirus) are 
members of a family of large, enveloped, positive sense single-stranded RNA viruses that 
replicate in the cytoplasm of animal host cells, causing principally respiratory or enteric 
diseases but in some cases neurological illness or hepatitis. Individual Coronaviruses 
usually infect their hosts in a species specific manner, mainly via respiratory and fecal-oral 
routes [1-3]. 
 
 
1.1.1. General overview 
 
     In the spring of 2003, when it became clear that a new human Coronavirus was 
responsible for the Severe Acute Respiratory Syndrome (SARS) [4,5], Coronaviruses 
became much more recognized. The name Coronavirus, coined in 1968, is derived from the 
corona (crown) like morphology of these viruses. Based on serological cross reactivity, 
Coronaviruses are divided into three genera, usually referred to as group I, II, and III. More 
recent genome sequence analysis has confirmed this grouping, and the identification of the 
SARS Coronavirus (SCoV) as a new subfamily within the Coronaviridae [6, 7]. 
Coronaviruses are enveloped viruses with round virions of approximately 80 to 120 nm in 
diameter. The most distinctive feature of this viral family is the genome size. 
Coronaviruses have the largest genome of all RNA viruses (approximately 29.7 kb). The 
positive-stranded RNA is complexed with the basic nucleocapsid (N protein) to form a 
helical capsid found within the viral membrane. The membranes of all Coronaviruses 
contain at least three viral membrane proteins. These are (i) the Spike protein (S protein), 
that forms the glycoprotein spike  on the virion surface, giving the virus its name; (ii) the 
membrane (M protein), a protein that spans the membrane three times and has a short N 
terminal ectodomain and a cytoplasmic tail; and (iii) the small and highly hydrophobic 
Envelope (E protein).  
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1.1.2. SARS Coronavirus Envelope (E) protein 
 
 
          The Coronavirus E protein is a small polypeptide, ranging from 8.4 to 12 kDa, which 
is only a minor constituent of virions. Owing to its small size and limited quantity, the E 
protein was recognized as a virion component much later than the other structural proteins. 
As a result, both the structure and function of the protein are currently unknown. 
        SCoV E protein differs substantially from other Coronavirus E proteins, as these 
proteins are extremely divergent across the Coronavirus groups (but are relatively 
conserved among members of a single group). Nevertheless, the same general architecture 
can be recognized in all E proteins: a short hydrophilic amino terminus (8–12 residues) 
followed by a large hydrophobic TMD (21–29 residues), and a hydrophilic carboxy 
terminus (39–76 residues) which constitutes most of the protein. The E protein of the SCoV 
E virus contributes in the pathogenesis of the virus for its importance in the viral budding. 
It is a small, 76 amino acid residues, integral protein with an unusually long hydrophobic 
stretch (25 - 30 amino acid residues), placed in between a hydrophilic N- and C-terminus, ≈ 
8 and ≈ 40 residues long, respectively. This protein is very important for viron envelope 
morphogenesis [8–10], and membrane insertion of the E protein occurs without cleavage of 
a signal sequence [11]. It was shown that the E protein of the SCoV and other 
coronaviruses [12, 13] localizes to the Golgi apparatus and ER. The E protein has the 
ability to dramatically change the morphology of the Golgi apparatus, which could explain, 
in part, the ability of the E protein to induce apoptosis [11, 14]. Viral morphogenesis and 
budding has been studied extensively. It was found that in the SCoV [15] and other 
coronaviruses [11, 12, 16–18] that the expression of M and E proteins are sufficient for 
production of virus-like particles. This fundamental observation proved that neither the 
nucleocapsid nor the viral spike are needed for viral budding. Furthermore, expression of 
Infectious Bronchitis Virus (IBV) or Mouse Hepatitis Virus (MHV) E protein on its own 
causes the release of vesicles containing E protein, thereby pointing to the importance of 
coronavirus E protein in the budding process [12, 18]. Finally, mutations in MHV E protein 
cause marked morphological changes in the resulting viruses [19]. The information 
currently available about the role of the E protein in the budding process is not complete. 
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Consequently, the exact function and mechanism of action of this small protein are 
unknown. Even so, there is some evidence suggesting that the SCoV [20, 21] and the MHV 
[22, 23] E protein may function as a cation selective ion channel, which is more permeable 
to cations than to anions. This channel forming property is contained in the amino terminus 
TMD of the SCoV E protein, which where known by Affinity purified polyclonal 
antibodies recognizing the N-terminal [20]. Moreover, hexamethylene amiloride inhibited 
the Human Coronavirus (HCoV) and MHV E protein ion channel conductance in the lipid 
bi-layer and also inhibited replication of the parent Coronaviruses in cultured cells [23]. 
     The length of the hydrophobic segment of SARS-CoV protein has posed a problem with 
respect to assigning a topology to that protein. The average length of a transmembrane      
α-helix is 21 residues [24], far shorter than the hydrophobic stretch of E proteins. In 
contrast, if a bend is formed by the long hydrophobic stretch, the resulting helices would be 
much shorter than average [25]. ]. Further investigation is needed to resolve the backbone 
structure and orientation of the transmembrane domain of the SARS coronavirus E protein 
in lipid bilayer. An early report suggested a C terminus in the outer site of the membrane 
and the N terminus in the inner site of the membrane for the Transmissible Gastroenteritis 
Virus (TGEV) E protein [26]. More extensive investigations of the MHV and IBV E 
protein concluded that the carboxy terminus of the protein is cytoplasmic (i.e., is situated in 
the interior of the virion) [11, 12]. More recent results with an epitope-tagged Murine 
Coronavirus (MCoV) E protein [27] are consistent with a topology model in which the 
TMD spans the lipid bilayer twice, whereby both termini of the protein reside in the virus 
lumen. A similar model was suggested for the SCoV E protein using immunofluorescent 
staining by Q. Yuan et al, it was found that both the amino and carboxy terminus of the 
SCoV E protein are exposed to the viral lumen [28]. 
 
 
1.2. Membrane proteins 
 
     Membrane protein is a protein molecule that is attached to, or associated with the 
membrane of a cell or an organelle. More than half of all proteins interact with membranes.  
 
 
  5 
 
1.2.1. The biology of membrane proteins 
 
 
     Integral membrane proteins are defined as having part of their structure the 
transmembrane domain (TMD) embedded in the lipid bilayer. Membrane proteins with at 
least one TMD account for 20 -30% of the proteins in almost every genome sequenced so far 
[29, 30]. In contrast to integral membrane proteins, non-integral membrane bound proteins 
usually bound to the membrane indirectly by interactions with integral membrane proteins or 
directly by interactions with lipid polar head groups. Although both types of proteins are 
known as membrane proteins. Transmembrane (TM) proteins are strategically located at the 
interface between the cytosol and the cell surrounding. As such, they mediate communication 
between both sides of the membrane and involved in the host biological functions.       
       One example is the relaying of signals across the cell membrane carried out by the vast 
family of G protein coupled receptors. These receptors function as molecular switches and 
transducers in a variety of signaling cascades and processes. Another major role of TM 
proteins is the transport of solutes across the membrane by pores, channels, and transporters. 
Examples of such proteins are (i) the Escherichia Coli (E. coli) multidrug resistance efflux 
transporter (EmrE), which confers resistance to a wide variety of toxicants by actively 
removing them from the cell; (ii) the Na+/H+ antiporter channel, which exchange one 
molecule for another, are involved in homeostasis of H+ and Na+ ions; (iii) the aquaporins 
(water channel) which conduct water molecules in and out through cell membranes.  
     Membrane proteins are also involved in processes important to the life of the cell, such as 
photosynthesis, and cell respiration. The high abundance and strategic location of membrane 
proteins has made them ideal targets for most of the pharmaceuticals in use today. This, in 
turn, requires detailed structural and biochemical information about membrane proteins.  
      Reliable information of this kind can be obtained by performing experiments in the 
natural environment of membrane proteins the lipid bilayer. This requirement is a major 
experimental obstacle, especially when it comes to structural biology of membrane proteins 
[31].                . 
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1.2.2. General structure of membrane proteins 
 
 
     Membrane proteins must perform complex signaling and transport functions within the 
strict confines of the lipid bilayer. But the lipid bilayer is a variable and its surface region is 
usually composed of charged groups, while the hydrocarbon core is highly hydrophobic. 
These conditions require a unique structural adaptation of membrane proteins to their 
environment. 
     As no hydrogen bonding groups are present in the hydrophobic environment of the 
membrane, formation of secondary structure hydrogen bonds is highly favorable. It is for 
this reason that within the lipid-embedded domain of membrane proteins only two major 
classes of secondary structures have been observed α-helical bundles and β-barrels. By far, 
the majority of membrane proteins belong to the former class composed of bundled           
α-helices. β-barrels, in contrast, are found only in the outer membranes of Gram-negative 
bacteria, mitochondria, and chloroplasts. The most important feature of both these 
structures is that they satisfy all their potential of creating backbone hydrogen bonding. 
Hydrogen bonds in α-helical structure are formed mostly between residues 1 and 1+4 of the 
same helical structure, while within the β-barrel structure; hydrogen bonds are formed 
between extended anti-parallel peptide strands.                    . 
     The TMD is optimized to interact favorably with lipid bilayer by exposing a 
hydrophobic surface that reflects the physicochemical properties of the surrounding 
hydrophobic lipid bilayer. As a consequence, TM proteins usually have a hydrophobic 
stretch which is long enough to span the hydrocarbon core of a typical bi-layer. In case of 
the common α-helical structure, the average length of a TMD was found to be 21-22 amino 
acids [24], corresponds to the average width of the lipid bi-layer. This value is valid for a 
canonical α-helical structure, but Transmembrane Domains (TMDs) exhibit more complex 
architecture as exemplified by the structure of the glycerol /water channel GlpF [32]. Most 
notable in the structure is the pair of helices that penetrate half way into the bilayer. The 
structure also contains a highly distorted TM helix, which is a common feature of 
membrane proteins, about 60% of all TM helices contain significant bends or other 
distortions, as predicted by Yohannan et al. [33]. Other deviations from ideal                      
α-helical structures are short stretches of π or 310 helix [34, 34]. These distortions lead to a 
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deviation of the helix axis and/or a change in the periodicity of side chain positions. It is 
possible that such distortions allow the small structural adjustments needed for precise 
positioning of functional groups. Non perfect helical structure may also provide weak 
points in the helical rods that facilitate movements needed for protein function (e.g., helix- 
breaking properties of Proline residues) [33, 35].                                                        . 
     Bitopic membrane proteins have one TMD, while polytopic membrane proteins have 
more then one α-helical TMD to integrate in the lipid bilayer. Bitopic membrane proteins 
are further categorized according to the orientation of their TMD. During biogenesis, the 
N-terminus of a type I integral membrane protein is in the Endoplasmic Reticulum (ER) 
lumen, whereas in a type II membrane protein the N-terminus is in the cytoplasm.               
A common structural feature found in many TM proteins is the high affinity of aromatic 
residues to the lipid-water interface. In polytopic membrane proteins and α-helical bundles 
these residues often form an aromatic belt a cluster of aromatic residues situated close to 
the lipid head groups 
 
 
1.2.3. Structural analysis of membrane proteins 
 
     The increasing use of computational methods for structural based drug design, together 
with the need to better understand the mechanism of action of a protein under question, 
have created an urgent need to determine the three-dimensional structure of membrane 
proteins. Despite being such an important and abundant class of proteins, as of October 
2006 there are only 116 unique atomic-resolution structures of membrane proteins (or 225 
structures if including non- unique structures). This number is negligible compared to the 
thousands of structures of water soluble proteins. The complete three-dimensional
 
structure 
of a protein at high resolution can be determined by X-ray crystallography. This technique 
requires
 
the molecule to form a well ordered crystal which is not
 
possible for all proteins. 
An alternative to X-ray
 
crystallography is multidimensional nuclear magnetic
 
resonance 
(NMR) spectroscopy. Using NMR spectroscopy structures
 
of the proteins can be 
determined in solution.
 
The interpretation of the NMR spectra of large proteins is very 
complex, so
 
its present application is limited to small
 
proteins (~15-25 kDa) [31]. Hence, 
elucidating the structure of membrane protein is still one of the biggest challenges facing 
  8 
the field of structural biology today.                   . 
     Many alternative approaches have emerged in order to tackle the problem of solving 
membrane proteins structure. This includes solid-state NMR spectroscopy and low-
resolution techniques such as vibrational spectroscopy, electron microscopy, electron 
paramagnetic resonance, and theoretical calculations.  
 
 
1.3. Peptide synthesis and purification 
 
     In order to study the secondary structure of the target peptide, using any of the methods 
mentioned above, it is important to synthesize this protein. The most accepted method for 
building  peptides in the lab is the Solid-phase synthesis method. To start working with the 
synthesized peptide it is important to obtain a highly pure  peptide, so purification of the 
synthesized peptide is the next step; using high performance liquid chromatography which 
will separate the pure peptide from impurities . 
 
 
1.3.1. Peptide synthesis 
 
     peptide synthesis is the creation of peptides, which are organic compounds in which 
multiple amino acids bind via peptide bonds which are also known as amide bonds, for the 
purpose of peptide synthesis, amino acids can be considered as having two main 
functionalities to manipulate, the amino and carboxyl groups. Functional groupings are also 
present in the side chains of many of the principle amino acids. These functionalities must 
be protected so that they do not interfere with the formation of the peptide bond, peptides 
are synthesized by coupling the carboxyl group or C-terminus of one amino acid to the 
amino group or N-terminus of another, there are two way for  the synthesis , the Liquid-
phase synthesis and the Solid-phase synthesis[36]. 
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1.3.1.1. Liquid-phase synthesis 
 
     Liquid-phase synthesis is used in large-scale production of peptides for industrial 
purposes synthesis of well known short peptides. It is a classical approach to peptide 
synthesis in solution, which has a long cycle time, and it has limitation in number of amino 
acids to be combined. 
So  it  has been replaced in most labs by solid-phase synthesis. 
 
 
1.3.1.2. Solid-phase synthesis 
 
      Solid-phase peptide synthesis (SPPS), pioneered by Merrifield in 1959, resulted in a 
paradigm shift within the peptide synthesis community. It is now the accepted method for 
building peptides and proteins in the lab in a synthetic manner. SPPS allows the synthesis 
of natural peptides, which are difficult to express in bacteria, the incorporation of unnatural 
amino acids, peptide/protein backbone modification, and the synthesis of D-proteins, which 
consist of D-amino acids, and synthesis 13C=18O amino acids.  
Small solid beads, insoluble yet porous, are treated with functional units (linkers) on which 
peptide chains can be built. The peptide will remain covalently attached to the bead until 
cleaved from it by a reagent such as trifluoroacetic acid. The peptide is thus immobilized 
on the solid-phase, and can be retained during a filtration process, whereas liquid-phase 
reagents and by-products of synthesis are flushed away. 
     The general principle of SPPS is one of repeated cycles of coupling-deprotection. The 
free N-terminal amine of a solid-phase attached peptide is coupled to a single N-protected 
amino acid unit. This unit is then deprotected, revealing a new N-terminal amine to which a 
further amino acid may be attached (Figure (1) ).There are two majorly used forms of SPPS 
-- Fmoc and Boc. Unlike ribosome protein synthesis, solid-phase peptide synthesis 
proceeds in a C-terminal to N-terminal fashion. The N-termini of amino acid monomers is 
protected by these two groups and added onto a deprotected amino acid chain [37]. 
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1.3.1.2.1. Fmoc SPPS  
    This method was introduced by Carpino in 1972 and further applied by Atherton in 
1978. Fmoc stands for Fluorenyl-methoxy-carbonyl which describes the Fmoc protecting 
group, first described as a protecting group by Carpino in 1970. The crucial link in any 
polypeptide chain is the amide bond, which is formed by the condensation of an amine 
group of one amino acid and a carboxyl group of another. Generally, an amino acid 
consists of a central carbon atom (called the α-carbon) that is attached to four other groups: 
hydrogen, amino group, carboxyl group, and a side chain group. The side chain group 
defines the different structures of amino acids. Certain side chains contain functional 
groups that can interfere with the formation of the amide bond. Therefore, it is important to 
mask the functional groups of the amino acid side chain, The N-termini of amino acid 
monomers is protected by Fmoc too. Removal of side-chain protecting groups and peptide 
from the resin is achieved by incubating in trifluoroacetic acid (TFA) [36]. 
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Figure (1.1):  peptide synthesis protocol showing the four main steps: Protection         
                       activation, coupling and selective de-protection and further extension.  
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1.3.2. Peptide Purification    
     Since the purity of the peptide obtained from the synthesis is sequence dependent, major 
impurities can range from 10% to 50% by weight. They consist of small water soluble 
molecules, salts and protecting groups from the cleavage reaction, deletion peptides created 
due to incomplete coupling during synthesis, and modified peptides created during the 
cleavage. These species can be removed using reverse phase HPLC. 
 
 
 
1.3.2.1. Reverse Phase Chromatography 
 
     In reverse phase chromatography, the packing is non-polar and the solvent is polar with 
respect to the sample. Retention is the result of the interaction of the non-polar components 
of the solutes and the non-polar stationary phase. Typical stationary phases are non-polar 
hydrocarbons, waxy liquids or bonded hydrocarbons, and the solvents are polar aqueous 
organic mixtures such as methanol-water or + acetonitrile-water. Silica is a reactive 
substrate to which various functionalities can be attached or bonded; the functionalities 
most widely bonded to silica are the alkyl (C18, C4 and C8), aromatic phenyl, and cyano 
and amino groups. The retention time is therefore longer for molecules which are more 
non-polar in nature, allowing polar molecules to elute more readily. Retention time is 
increased by the addition of polar solvent to the mobile phase and decreased by the addition 
of more hydrophobic solvent. Reverse phase chromatography operates on the principle of 
hydrophobic interactions which result from repulsive forces between a relatively polar 
solvent, the relatively non-polar analyte, and the non-polar stationary phase. The driving 
force in the binding of the analyte to the stationary phase is the decrease in the area of the 
non-polar segment of the analyte molecule exposed to the solvent.          
     The hydrophobic effect is decreased by adding more non-polar solvent into the mobile 
phase. This shifts the partition coefficient such that the analyte spends some portion of time 
moving down the column in the mobile phase, eventually eluting from the column [38]. 
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1.4. Vibrational spectroscopy 
 
Vibrational spectroscopy is a collective term used to describe two analytical techniques – 
infrared and Raman spectroscopy.  These techniques are used to measure the vibrational 
energy levels in a sample.  These energy levels are associated with the chemical bonds in a 
sample.  The spectrum (the output of the spectrometer) of a sample is unique, like a 
fingerprint.  
 
 
 
1.4.1. ATR-FTIR spectroscopy 
 
 
     The Infra-Red (IR) range of the electromagnetic spectrum (2.5 um - 700 nm) 
corresponds to the energies of vibrational transitions in molecules. These transitions are 
sensitive to the nature of the chemical bond (e.g., type of atoms, single- or double-bond, 
resonance), the chemical environment (e.g., hydrogen bonding, electrostatic properties, 
inter or intra-molecular interactions), and the orientation of the molecule relative to the IR 
radiation. These, together with the sensitivity of modern spectrometers, make Fourier 
Transform Infra-Red (FTIR) spectroscopy a popular tool for molecular analysis.                   
. 
     FTIR spectroscopy is particularly useful for membrane protein studies as it allows the 
analysis of such proteins as it is in their native environment, the lipid bilayer. This is 
because the lipid environment does not perturb the resolution or sensitivity of the spectra. It 
is also possible to simultaneously study the lipid bilayer, as there is no overlap between the 
absorption frequencies of the membrane and the embedded protein. By measuring the 
frequencies of the protein vibrational modes, mainly that of the amide I mode, one can 
determine the average secondary structure of the protein from its IR spectrum. Amide I is 
the
 
most intense absorption band in proteins. It is primilary goverend by the stretching 
vibration of the C=O (70-85%) and C-N
 
groups (10-20%). Its frequency is found in the 
range between 1600 and 1700 cm
-1
. The exact band position is determined by the backbone 
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conformation and the
 
hydrogen bonding pattern.                                     .  
Amide II is found in the 1510 and 1580 cm
-1
 region and it is more complex than amide I. 
Amide II derives mainly from in-plane N-H
 
bending (40-60% of the potential energy). The 
rest of the potential energy arises from the C-N (18-40%)
 
and the C-C (about 10%) 
stretching vibrations.                                                .  
Amides III, V are very complex bands
 
dependent on the details of the force field, the nature 
of side chains and hydrogen bonding. Therefore these
 
bands are of little use. However, on 
the secondary structure of the protein, since the backbone C=O group is involved in 
different hydrogen bonding in different secondary structures. As a result, the 
experimentally observed amide I band can be generally classified as follows: 1662-1645 
cm-1 for α-helices, 1689-1682, and 1637-1613cm-1 for β-sheets, and 1682-1662cm-1 
for turns as shown in Figure (1.2). Among the various IR techniques, Attenuated Total 
internal Reflection Fourier Transform Infra-Red (ATR-FTIR) is one of the most useful 
methods for obtaining spectroscopic data on biological membranes [39]. In this type of 
measurements the incoming light beam is completely reflected when it impinges on the 
surface of the internal refection element (Figure 1.3). Within this element, a standard wave 
is established normal to the reflecting surface. Consequently, the standing wave generates 
an electromagnetic disturbance that exists in the rarer medium beyond the reflecting 
interface. This so called evanescent wave is characterized by its amplitude, which falls off 
exponentially with the distance from the interface [40] and is affected (i.e., absorbed) by 
the sample on the surface of the ATR element. 
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Figure (1.2): ATR-FTIR spectra corresponding to the amide I region shows Peaks  
                      of α-helical peptide segment in gray , β-strand peptide segment in  
                      orange and random coil peptide segment in violet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (1.3): The trapezoid ATR element and the incident polarized light. The  
                      polarized light (parallel in red or perpendicular in blue) is reflected  
                      22 times within the confines of the internal reflection element. The  
                      evanescent wave interacts with the sample deposited on the surface  
                      of the crystal. 
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        The polarized Light can be defined as the light that has a dominant direction in on 
plane. Natural light is not polarized, while laser beam is polarized.  
 
 
 1.4.2. Site-specific isotope labeling 
 
 
     Low spectral resolution is one of the major drawbacks of IR spectroscopy as a tool for 
structural studies of biological macromolecules. Biological samples usually contain a 
population of chemical bonds which differs slightly from one another (e.g., the peptide 
bond). Because of this, the absorption band of the whole population is usually much wider 
than the absorption band of a single vibrational transition. The structural information 
obtained from such measurements is therefore an average property of the macromolecule. 
    A possible solution for the low resolution problem is the use of site-specific 
isotope labeling [41]. An isotopic label shifts the absorption band of the labeled site 
to a transparent region of the spectrum, without altering the chemical nature of the 
molecule. For example, site-specific isotope labeling of a backbone C=O group, 
together with the sensitivity of the Amide I vibrational mode to the protein 
secondary structure, allow the measurement of local conformation at the level of a 
single residue [42].                     .  
     The isotopic labels that have been used so far are the GlyCD2 [43], the triple    C-
deuterated methyl group of alanine [44], and most frequently, the carbonyl group of the 
peptide bond. The carbonyl group can be labeled in two different ways with the 13C=16O 
label [45-48] or with the 13C=18O label [45, 49-51]. The 13C=18O label has two 
major advantages over the 13C=16O label. 
1. The -40 cm-1 shift of the absorption band due to 13C=16O incorporation yields an 
isotope- edited mode present only as a shoulder on the unlabeled C=O peak. On the other 
hand, the frequency shift of -65 cm-1 arising from the double label places the 13C=18O 
absorption band so that it is nearly baseline resolved from the much larger unlabeled peak.                  
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2. Because of the high natural abundance of 13C=16O  (1.1%), in a spectrum of a protein 
over 45 amino acids long, 50% of the isotope-edited peak is due to naturally-occurring 
isotope.  In contrast, the natural abundance of the 13C=18O label (0.0026%) is negligible, 
so that the IR absorption of the 13C=18O amide I normal mode is absolutely unique to the 
labeled site.  
 
 
1.4.3. Site-specific infrared dichroism 
 
     Site-specific dichroism is a vibrational spectroscopy technique proposed by Arkin et al. 
[45], that utilizes site-specific isotope labeling and polarized IR light. Dichroism (Equation. 
1.1) is defined as the ratio between the absorption of parallel and perpendicular polarized 
light: 
 
 
                                                  
Equation (1.1): Dichroism which is defined as the ratio between the absorption of parallel 
and perpendicular polarized light 
 
 
 
     This new vibrational spectorscopy technique is based on site-directed isotope labeling 
and site-specific infrared dichroism (SSID). In SSID not only frequencies of the labeled 
sites measured, but the dichroism as well, yielding site-specific orientational restraints. The 
orientation of a single vibrational mode in an α-helix, represented as vector P in Figure 
(1.4), can be expressed as a function of several parameters: (i) the helix tilt angle β, (ii) the 
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angles α and δ relating the helix axis and the vibrational mode, and (iii) the rotation angle 
ω of the helix about its axis. 
 Isotope label shifts the frequency of a specific vibrational mode so that its dichroism may 
be directly measured. This analysis is aided by the fact that the relative rotational pitch 
angles of the labeled sites are known: in α-helices, consecutive sites are related by a 100° 
rotation [44].Subsequently, a structural model is derived by combination of experimental 
data, obtained from SSID, and implementation of the resulting restraints as energy 
refinement terms in a molecular dynamics simulation [46]. Site-directed dichroism enables 
the determination of the helix tilt angle, β, and pitch angle, ω, from two selectively labeled 
oriented samples.   
 
     Isotopically labeled probes are most suitable for the use of exploring the secondary 
structure of proteins in as much as they do not change the native properties of the protein, 
and yield interpretable structural information. SSID has already been used successfully in 
the studies of the transmembrane domain of several proteins [44]. The dichroic ratio of the 
helix is calculated by using the amide I absorption band of the canonically distributed α-
helical C=O transition dipole moment centered at ≈1657 cmˉ¹ [39].  
 
     The dichroism of the labeled site is calculated by using the shifted vibrational 
mode (60 cm-1 for the 13C=18O Amide I label). The measured dichroism yields 
orientational restraints that are later used as energy refinement terms in molecular 
dynamics simulations).  
 
      Examples of the use of site-specific isotope labeling with ATR-FTIR are the studies on 
the transmembrane domain of GPA [44], Influenza AM2H+ Channel [47], Human 
Immunodeficiency Virus type 1 (HIV-1) vpu protein [46], Influenza C virus CM2 protein 
[48], Phospholamban [49], the T-cell receptor CD3- [38, 43-46, 51, 52], and the 
transmembrane domain of the trimeric major histocompatibility complex class II-associated 
invariant chain [45]. 
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Figure (1.4): (a) A schematic diagram of a helix containing two C=O bonds  
                      (exaggerated in length for illustrative purposes). The relative  
                      orientation of the two bonds, with respect to the z axis, changes upon  
                      tilting the helix by the angle β, as well as changing the rotational  
                      pitch angle of the helix about its axis by the angle ω. (b) The explicit  
                      diagram used in the mathematical derivations of a helix tilted from  
                      the z axis by the angle β, containing a vibrating bond, 
→
P, related to  
                      the helix director by the angles α and δ. The bond is positioned with  
                      a rotational pitch angle ω around the helix director. 
. 
 
 
 
1.5. Prediction of transmembrane domains 
 
 
       Although the lipid bilayer is an obstacle for structure determination by experimental 
methods, it has greatly simplified sequence based prediction of TMDs. Hydrophobic 
residues are a clear majority in transmembrane helices, which makes hydrophobicity an 
important feature in defining TM helices. The basic assumptions in TMD recognition are 
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that stretches of about 20 consecutive hydrophobic residues can span the membrane, and 
that such stretches can be easily recognized in protein sequences. 
     Many hydrophobicity scales have been developed over the past decade on the basis of 
solubility measurements of the amino acids in different solvents (i.e., water and 
hydrophobic solvent), vapor pressure of side chain analogues, analysis of side chain 
distribution within soluble and TM proteins, and theoretical energy calculations. Two of 
the most frequently used hydrophobicity scales are those introduced by Kyte and Doolittle 
in 1982 [53], and by Engelman et al. (the GES scale) in 1986 [54]. Another hydrophobicity 
scale was recently suggested by Zviling et al. [55], who used genetic algorithm for 
calculating an optimized hydrophobicity scale. When used alone, the simple 
hydrophobicity of TM residues can predict about 80% of TM helices. This is compared to 
much more accurate algorithms, based on neural-network [56] or hidden Markov model 
methods [30], which can predict >97% of TM helices. These predictors take advantage of 
evolutionary data from multiple sequence alignments and consider sequence elements in 
order to refine TMDs identification. 
 
 
1.6. Global search molecular dynamics simulation 
 
     Molecular interactions between transmembrane α-helices can be explored using global 
searching molecular dynamics simulations (GSMDS), a method that produces a group of 
probable low energy structures, limiting the number of possible conformations. Brunger 
and co-workers [49, 57] have developed a procedure to explore transmembrane helix 
interactions based on global searching molecular dynamics simulations. In this method, 
multiple symmetric bundles of helices are constructed, each differing from the other by the 
rotation of the helices about their axes. These are then used as starting positions for 
molecular dynamics and energy minimization protocols. The output structures from these 
simulations are compared and grouped into clusters that contain similar structures. An 
average of the structures forming a cluster represents a model with characteristic 
interhelical interactions and helix tilt[58].  
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     The correct model is selected amongst the several different clusters, based on existing 
experimental data, either from mutagenesis or orientational data from site specific infrared 
dichroism used as spatial restraints. Alternatively, they have also used a purely 
computational approach where simulations are performed on close sequence variants that 
are likely to share the same structure [59]. 
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CHAPTER 2 
 
PURPOSE OF THE THIS WORK 
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2.1. The main purposes of this study are: 
 
 Analyzing the secondary structure of the transmembrane domain of SARS CoV E 
protein using a new biophysical method which is called (Attenuated Total Internal 
Reflection-Fourier Transform Infrared spectroscopy) (ATR-FTIR). 
 
 
  Further study of the hairpin conformation of the E protein of SARS CoV as postulated 
by Arbely et al [26], in which he showed that the iodinated phenylalanine 23 was 
displaced about 16.5A° from the bi-layer center in the lipid head group region. 
 
 
 Using Multiple site specific infrared dichroism, in which the transmembrane domain  
had been labeled at multiple positions along the sequence with  multi labeled amino 
acids with (13C=18O), which allow gathering of information at different points along 
the helix, and provides accurate information about the backbone of the secondary 
structure of the transmembrane proteins  
 
 
 Suggest a model for the structure of the SCoV E protein TMD. 
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3. Materials and Methods 
 
 
3.1. Instrumentation: 
 
 Systems for the synthesis of the peptide, which represents the transmembrane 
domain of SARS CoV E protein. That include the Fmocing system, to protect 
the N-terminus group of the amino acids, and system for amino acids labeling 
with 13C=18O. 
 
 High Performance Liquid Chromatography (HPLC) Waters Breeze HPLC 
System with binary pump for the purification of the E protein with two detectors 
UV and fluorescence detectors using Jupiter 5µ C4-300Ǻ column (Phenomenex, 
Chesire, UK) 
  
 
 Mass Spectrometer, Trace Ms, from Thermo Quest, Finnigen. 
 
 Fourier Transform Infrared Spectroscopy machine, Nicolet Avatar E.S.P. FT-IR 
Spectrometer from Thermo Electron Corporation, with DTGS detector. 
 
 Fourier Transform Infrared Spectroscopy machine, Nicolet Magna-560 infrared 
spectrometer (Nicolet Instrument, Madison) purged with N2 and equipped with 
a MCT-A detector cooled with liquid nitrogen. 
 
 Attenuated Total internal Reflection unit (ATR) a 25 reflections ATR accessory 
from Grasbey Specac (Kent, UK) and a wire grid polarizer (0.25 μM, Graseby 
Specac). 
 
 Germanium (Ge) trapezoidal internal reflection element   (50×2×10 mm). 
 
 Integration program origin pro 7.0 (OriginLab Corporation. Northampton, MA) 
software for the peak fitting and integrating areas under peaks. 
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 Freeze Drying machine (Lyophilizer) from Labconco. 
 
 Rotary Evaporator from Labconco. 
 
 
 
 Bench top pH meter from (WTW). 
 
 
 Analytical balance from Sartorius CP. 
 
 
 Ultra pure water system from NANO pure Diamond.  
 
 
  
 
 
3.2. Materials and chemicals  
 
 1,2-dimyristoyl-sn-glycero-3-phosphocholine, (DMPC), was obtained from 
Avanti Polar Lipids in powder form. 
 
 Hexafluoro-2-propanol, purity ≥99.8% HPLC grade (HFIP), was obtained from 
Merck. 
 
 Trifluoroacetic Acid, (TFA), for HPLC, ≥99.0% (GC), was obtained from 
Aldrich. 
 
 Anhydrous dioxane, 99.8%, was obtained from Aldrich. 
 
 Heavy water, H2
18O, (95% 18O), was obtained from ISOTEC. 
 
 Argon gas. 
 
 Sulfuric acid, purity 99.9% was obtained from Aldrich. 
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 Calcium chloride anhydrous, 99.99%, was obtained from Aldrich in powder 
form. 
 
 Hydrochloric acid, 37%, AR grade , was obtained from Aldrich. 
 
 Acetonitrile, Chromasolv grade, for HPLC, ≥99.9%, was obtained from Sigma-
Aldrich.  
 
 2-Propanol, Chromasolv grade, for HPLC, ≥99.8% (GC), was obtained from 
Sigma-Aldrich. 
 
 Potassium Carbonate, anhydrous, 99.99%, was obtained from Aldrich in powder 
form. 
 
 9-fluorenylmethoxycarbonyl-Cl, (Fmoc-Cl), was obtained from Fluka, Buchs, 
Switzerland. 
 Ether, was obtained from Sigma-Aldrich, St. Louis, Mo, USA. 
 
 Ethyl acetate, HPLC grade, ≥99.8% was obtained from Sigma-Aldrich, St. 
Louis, Mo, USA. 
 
 Magnesium sulfate, anhydrous, was obtained from Mallinckrodt Baker, St. 
Louis, MO, USA. 
 
 Petroleum ether ACS reagent was obtained from Sigma-Aldrich. 
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3.3. Methods 
  
3.3.1.   13C=18O labeling 
 
 
      All labeling reactions were performed in dry environment and under continuous flow of 
Argon gas to prevent any evaporation from the reaction. In a typical experiment, 3.57 × 
10−3 mol of amino acid was dissolved in a mixture of 10 ml anhydrous 1, 4-dioxane 
(Sigma-Aldrich, St. Louis, Mo, USA) and 1 ml of H2
18O. The mixture was stirred in ice-
cold bath and acidified by bubbling dry HCl (g) Equation (3.1). Dry HCl (g) was generated 
by drop wise addition of 10 ml H2SO4 (99.9%) to 10 gr of CaCl2, and bubbling the 
evolved HCl (g) through the reaction mixture for 20 min. The acidified mixture was stirred 
under reflux for 2 hr as shown in figure (3.1), cooled to room temperature, evaporated 
under reduced pressure and lyophilized over night. 
The labeling was confirmed by mass spectroscopy for the amino acids and also for the 
heavy water. 
 
 
 
 
 
Equation (3.1): labeling reactions equation shows labeling of the amino  
                           acids with 18O using the heavy water H2
18O. 
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Figure (3.1): schematic diagram shows the labeling system for the amino acids              
                     with 13C=18O labeling. 
 
 
 
3.3.2. FMOC protection 
 
 
     The product of the 13C=18O labeling reaction (3.57×10−3 mol of amino acid) was 
used for the FMOC protection reaction Equation (3.2) without any further purification. The 
amino acid was dissolved in a mixture of 25 ml K2CO3 solution (13 gr/100 ml; BDH 
Laboratory Supplies, Poole, England) and 11 ml 1, 4-dioxane (Sigma-Aldrich, St. Louis, 
Mo, USA). (14.3 gr) of Fmoc-Cl (Fluka, Buchs, Switzerland) was dissolved in 11 ml 1, 4-
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dioxane and the solution was added drop wise to the reaction mixture, stirred in an ice bath. 
The reaction was allowed to warm to room temperature and stirred over night. The solution 
was then diluted with water, washed three times with ether (Sigma-Aldrich, St. Louis, Mo, 
USA), and the combined ether extracts washed twice with brine. The combined water 
extracts were cooled in an ice-bath and acidified by adding dilute HCl (aq) and washed 
three times with ethyl acetate (Sigma-Aldrich, St. Louis, Mo, USA).The combined ethyl 
acetate extracts were washed with brine, dried over MgSO4(s) (Mallinckrodt Baker, St. 
Louis, MO, USA), filtered, evaporated under reduced pressure and lyophilized over night. 
The dry product was recrystallized using the solvent system described in Table (3.1). 
 
 
 
 
Equation (3.2): FMOC protection reaction Equation to protect the N- 
                           terminus group of the amino acids and system for the  
                           labeled amino acids with 
13
C=
18
O. 
 
 
Fmoc-amino acid Solvent system 
Fmoc-Ala-OH EtOAc – Petroleum ether 
Fmoc-Gly-OH CH2Cl2 – Petroleum ether 
Fmoc-Ile-OH CH2Cl2 – Petroleum ether 
Fmoc-Leu-OH CH2Cl2 – Petroleum ether 
Fmoc-Phe-OH EtOAc – Petroleum ether 
Fmoc-Val-OH CH2Cl2 – Petroleum ether 
 
 
 
Table 3.1: The solvent system used for recrystallization of FMOC protected and  
                 13C=18O labeled amino acids. Recrystallized amino acids were filtered  
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                 and dried over night under reduced pressure. 
 
 
3.3.3. Protein synthesis 
 
     Peptides encompassing the predicted transmembrane domain of SARS coronavirus E 
protein (Figure (3.2), residues 7 to 38 (Figure (3.3) were synthesized by standard solid-
phase N-(9- fluorenyl) methoxycarbonyl chemistry in Keck Foundation Biotechnology 
Resource Laboratory (Yale University). The peptides were cleaved from the resin with 
trifluoroacetic acid (TFA, Aldrich) and lyophilized.  
 
 
 
 
 
 
 
Figure (3.2): diagram of the of SARS coronavirus E protein, outlining the  
                      synthesized transmembrane domain region from residue 7 to 38. 
 
 
 
 
 
 
 
 
 
 
 
Figure (3.3): diagram of the synthesized transmembrane domain region from  
                       residue 7 to 38 of the SCoV E protein outlining the labeled residues  
                       by yellow shading. 
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3.3.4. Protein purification 
 
     The crude peptide was dissolved in trifluoroacetic acid (TFA) (final concentration about 
5 mg/ml) and immediately injected on Jupiter 5µ C4 300Å HPLC column phenomenex in 
order to be purified with the semi-preparative reversed phase high pressure liquid 
chromatography. The products were equilibrated with 80% H2O, 8% (v/v) acetonitrile (and 
12% (v/v) 2- propanol (Peptide elution was achieved with linear gradient to a final solvent 
composition of 40% (v/v) acetonitrile, and 60% (v/v) 2-propanol. All solvents contained 
0.1% (v/v) TFA. The eluent was collected over a period of 5 minutes from the 20
th
 minute 
to the 25
th
 minute as shown in Figure (3.4), Table (3.2). In each case, the primary peak 
which contains the synthesized TMD of SARS CoV E protein was well separated from the 
other peaks. As seen in Figure (3.5) the peptide peak and the TFA peak were both detected 
by the UV detector, but in the fluorescence detector the peptide peak was more easily 
detected because of the presence of Phenylalanine  (Phe) which has fluorescence properties 
at (excitation 257nm, emission  282nm) as shown in Figure (3.6). Peptide purity was 
confirmed by mass spectrometry. 
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               Time(min)  Hydrophilic 
phase % 
Hydrophobic 
phase  % 
 Flow rate: 
ml/min 
Initial 80 20  0.1 
1 80 20 3.0 
9 80 20 3.0 
21 0 100 3.0 
28 0 100 3.0 
30 80 20 3.0 
33 80 20 3.0 
34 80 20 0.1 
 
Table (3.2): The gradient of the pumped solvents used in the HPLC purification,  
                     the hydrophilic phase has the water, and the hydrophobic phase 
                     has the acetonitrile and 2-propanol. 
 
Figure (3.4): Schematic diagram shows the gradient of the solvents used in the  
                      HPLC process; the hydrophilic phase has the water, where the  
                      hydrophobic phase has the acetonitrile and 2-propanol. 
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Figure (3.5): HPLC chromatogram of the crude peptide show the peptide peak  
                      obtained at the 20-25 min region and the trifluoroacetic acid peak  
                      obtained at the 8-13 min region using UV detector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (3.6): HPLC chromatogram of the crude peptides shows the peptide peak  
                      at the 20-25 min using fluorescence detector. 
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3.3.5. Lyophilization (Freeze Drying) 
 
 
      Lyophilization is the process of isolating a solid substance from solution by freezing the 
solution and evaporating the ice under vacuum, it is carried out using a simple principle of 
physics called sublimation. Sublimation is the transition of a substance from the solid to the 
vapor state, without passing through an intermediate liquid phase. 
 
     To lyophilize the purified peptide, it was frozen by putting it a in round bottom flask 
using liquid nitrogen and rotating machine, in the presence of 10 mM HCl (to remove 
traces of TFA adducts) then it was left over night at 3x 10-3 m bar in the dry freezing 
machine. 
 
 
 
3.3.6. Reconstitution of peptide in the vesicles 
 
 
     After over night lyophilization of pooled fractions in the presence of 10 mM HCl, 1 mg 
of the dried peptide was dissolved in a solution that contain, 10 mg 
dimyristoylphosphocholine (DMPC, Avanti) in 900 ml of 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP, Merck). The solvent was evaporated over night under reduced pressure, by 
means of a rotary evaporator. One milliliter of H2O was added to the dried product and the 
solution was mixed for 20 minutes at 30 °C, then the vesicles were spread on the 
Germanium trapezoidal internal reflection element, and dried for 30 min in dry air flow. 
 
 
 
3.3.7. FTIR spectroscopy 
 
      Data were recorded on a Nicolet Magna-560 infrared spectrometer (Nicolet Instrument 
Corporation, USA) purged with dry air and equipped with an MCTA detector, cooled with 
liquid nitrogen. A total of 1000 interferograms were collected at a resolution of 2 cm-1. 
Attenuated total reflection (ATR) spectra were measured with a 25 reflections ATR 
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accessory from Grasbey Specac (Kent, UK) and a wire grid polarizer (0.25 µM, Graseby 
Specac). Three hundred microlitres of sample (1 mg/ml of peptide and 10 mg/ml of lipid) 
were deposited onto a Ge trapezoidal internal reflection element (50×2×10mm) flowed by 
removal of bulk solvent. For the purpose of solvent exchange, air was followed over the 
sample that was bubbled through 
2
H2O or H2O. Transmission FTIR spectra were 
collected by depositing    50 µl of sample (1 mg/ml of peptide and 10 mg/ ml of lipid) on a 
CaF2 window. The dichroic ratios of the Amide I band were calculated by integrating 
between 1670 cm-1 and 1645 cm-1. All integrations were performed by using a straight 
baseline that contains points immediately before and after the band. Reported standard 
deviations values represent a minimum of two data sets measured. 
 
 
3.4. Protein prediction programs 
 
 
     Computational studies have been successful at predicting helical membrane protein 
topologies, i.e., identifying helical TM domains and predicting their in/out orientation 
relative to the membrane. It was based on the hypothesis that hydrophobic protein portions 
could form stable structures across the bilayer using hydrophobic helices.  
  
    Two general observations have been useful for predicting TM regions and their 
topologies.  I.  Hydrophobic residues are enriched in TM helical segments where they 
traverse the hydrophobic region of a membrane. II. Cytoplasmic segments contain 
significantly more positive charges than periplasmic segments. 
  
    Predict protein server is an Internet service for sequence analysis and the prediction of 
protein structure and function. Users submit protein sequences or alignments. The servers 
  37 
return multiple sequence alignments predictions, for transmembrane helices, or coiled-coil 
regions, or predictions of transmembrane strands, via e-mail to the users. 
 
We used three different prediction severs: 
1. The PSIPRED Protein Structure Prediction Server. 
2. Predict Protein server. 
3. Membrane Protein Secondary Structure Prediction Server. 
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CHAPTER 4 
 
RESULS AND DISCUSSION 
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4.1. Results 
 
 
4.1.1 FTIR spectroscopy evidence that the E protein of SARS CoV is an α-helix 
 
 
         In an effort to better understand the structure of the TMD of SARS CoV E protein, 
we decided to structurally analyze the transmembrane domain of E protein using FTIR 
spectroscopy. After over night lyophilization of pooled fractions in the presence of 10 mM 
HCl to remove traces of TFA adducts. ATR-FTIR spectra were obtained using both parallel 
and perpendicular polarized light. In the FTIR spectrum (1600– 1700 cmˉ¹) it is important 
to focus on the amide I vibrational mode as shown in Figure (4.1, 4.2, and 4.3). The amide 
I vibrational mode comes mostly from the peptidic C=O stretch, which correlates to the 
secondary structure of the protein. Peaks resonating at 1655 cmˉ¹, 1630 cmˉ¹ and 1645 
cmˉ¹ correspond to α-helical, β-strand and random coil peptide segments, respectively [39].  
The locations of both the amide I and amide II bands are sensitive to the secondary 
structure content of a protein. 
 
The amide I mode of SCoV E protein TMD is centered at 1657 cmˉ¹ with a peak width at 
half height of 23 cmˉ¹, which indicates that the E protein has a very high helical content, 
and the absence of any other secondary structure component. 
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Figure (4.3): ATR- FTIR  spectra  of   isotopically     labeled   sites in   SARS  
                      coronavirus E protein transmembrane domain peptide reconstituted  
                      in lipid bilayer focusing on the amide I region, with 13C=18O labels   
                      at amino acids A: 13, B: 17, C: 18, D: 21, E: 24, F: 25, G: 28, H: 33. 
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4.1.2. 26 Residues of the E protein are embedded in the lipid bilayer  
 
      Hydrogen isotope exchange is becoming a powerful tool for studying the protein 
embedded in the lipid bilayer, where the exchange of the hydrogen with the deuterium that 
present in the heavy water occurs. The deuterium has nearly identical chemical properties 
to that of the hydrogen [51]. 
   When a polypeptide folds to form the well-defined secondary structure of a protein, many 
of the amide hydrogens become buried in the lipid bilayer and no longer come into direct 
contact with the solvent water. This causes a marked decrease in the rate of exchange for 
these hydrogen.     
     FTIR spectroscopy is a good method to describe the extent of membrane incorporation 
of transmembrane proteins. This can be done by observing the reduction in any vibrational 
mode containing significant contributions from the amide proton (e.g II mode: peptidic N–
H deformation) by changing the solvent from H2O to D2O. Because the lipid bilayer 
protects the peptide from exchanging the hydrogen (1H) with heavy hydrogen (deuterium, 
2H), and the exchange occurs only in the areas exposed to the solvent. All the vibrational 
modes that contain the N–D group will shift elsewhere and H /D exchange can be 
quantitated by measuring the reduction in the amide II mode directly, upon flushing the 
membrane with air saturated with D2O for several hours, the reduction in the amide II 
peak, centered at 1545 cmˉ¹, is reduced as shown in Figure (4.4), amide I is primilary 
governed by the stretching vibration of the C=O (70-85%) and C-N groups (10-20%), 
where the amide II which is more complex derived mainly from N-H bending (40-60% of 
potential energy), the rest potential energy arises from the C-N (18-40%) and C-C (about 
10%) stretching vibrations[52].  
          We can calculate the extent of exchange by normalizing both spectra (in H2O and 
D2O) on the amide II peak. The resulting exchange rate of 19 ± 2% is indicative of only 
six out of 32 residues in the peptide undergoing H /D exchange. This means 26 residues of 
SCoV E protein are protected from exchange as a result of their being embedded in the 
lipid bilayer.  
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4.1.3. Data analysis and calculations  
 
 
         Calculation of the data measured by the ATR- FTIR spectroscopy was analyzed using 
an advanced computer program (OriginPro 7 (SR2) from OriginLab™). This program can 
integrate and fit the peaks of interest.  
  
    Using this program, we determined the position for each peak center of the helix and for 
the labeled sites (with 13C=18O at residues No. 12 to 14, 17 to 29, 31, 33, and 34 of the 
SARS E protein), The average value for the center of the peaks was found to be at 1657 
cm-1 for the helix, and at 1592 for the labeled sites, in saturated air with both H2O and 
D2O. As shown in tables   (4.1-4.4). 
 
The area under the helix and the sites labeled with 13C=18O were determined in the 
synthesized TMD of the SARS Coronavirus E protein using the same program.  
Integrations of the area under the peaks of the helix and the site started from 1702 cm-1 to 
1620 cm-1 for the helix peak, and from 1602 cm-1 to 1582 cm-1 for the labeled sites peaks, 
in saturated air with H2O or D2O. As shown in tables   (4.5, 4.6, 4.8, 4.9). 
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Amino 
acid 
position 
Labeled Site peak 
center in  cm-1 
Helix peak 
center in  cm-1 
Leu 12 -- 1657 
Ile 13 1592 1658 
Val 14 1596 1659 
Val 17 1590 1658 
Leu 18 1591 1658 
Leu 19 1593 1659 
Phe 20 1596 1659 
Leu 21 1593 1657 
Ala 22 1595 1658 
Phe 23 1596 1659 
Val 24 1592 1659 
Val 25 1593 1657 
Phe 26 1585 1657 
Leu 27 1590 1660 
Leu 28 1591 1658 
Val 29 1596 1657 
Leu 31 1581 1659 
Ile 33 1597 1658 
Leu 34 1607 1659 
 
 
Table (4.1): Determination of the Position of the peak’s centers of the helix and the  
                    sites labeled with 13C=18O labels in H2O saturated samples (A).(residue No.  
                     12 has very weak label, and did not has peak for the labeled site)  
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Amino 
acid 
position 
Labeled Site peak 
center in  cm-1 
Helix peak 
center in  cm-1 
Leu 12 -- 1659 
Ile 13 1592 1658 
Val 14 1596 1659 
Val 17 1590 1658 
Leu 18 1591 1657 
Leu 19 1593 1659 
Phe 20 1596 1659 
Leu 21 1593 1657 
Ala 22 1595 1658 
Phe 23 1596 1659 
Val 24 1592 1658 
Val 25 1593 1657 
Phe 26 1584 1657 
Leu 27 1590 1659 
Leu 28 1591 1658 
Val 29 1597 1657 
Leu 31 1581 1658 
Ile 33 1597 1658 
Leu 34 1605 1658 
 
Table (4.2): Determination of the Position of the peak’s centers of the helix and the  
                    sites labeled with 13C=18O labels in H2O saturated samples (B). (residue No.  
                     12 has very weak label, and did not has peak for the labeled site)  
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Figure (4.5.a):  Schematic diagram showing the Position of peak’s centers of the  
                       helix and the labeled site with 13C=18O labels of the synthesized  
                       TMD of the SCoV E protein in ATR-FTIR spectrum in H2O  
                       saturated air sample table (4.1), the two arrows pointed at residues No. 26  
                       and 31 Phe  and  Leu  respectively. 
 
 
 
 
 
 
 
 
 
Figure (4.5.b):  Schematic diagram showing the Position of peak’s centers of the  
                       helix and the labeled site with 13C=18O labels of the synthesized  
                       TMD of the SCoV E protein in ATR-FTIR spectrum in H2O  
                       saturated air samples table (4.2), the two arrows pointed at residues No. 26  
                       and 31 Phe  and  Leu  respectively. 
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Amino 
acid 
position 
Labeled Site peak 
center in  cm-1 
Helix peak 
center in  cm-1 
Leu 12 --- 1656 
Ile 13 1593 1659 
Val 14 1597 1659 
Val 17 1591 1658 
Leu 18 1591 1658 
Leu 19 1593 1659 
Phe 20 1596 1658 
Leu 21 1593 1657 
Phe 23 1596 1659 
Val 24 1592 1659 
Val 25 1591 1658 
Phe 26 1584 1657 
Leu 27 1590 1660 
Leu 28 1591 1658 
Val 29 1596 1658 
Leu 31 1580 1659 
Ile 33 1597 1658 
Leu 34 1602 1659 
Average 1592 1658 
 
Table (4.3): Determination of the Position of the peak’s centers of the helix and the  
                     sites labeled with 13C=18O labels in D2O saturated samples (A). (Residue  
                    No. 12 has very weak label, and did not has peak for the labeled site)  
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Amino 
acid 
position 
Labeled Site peak 
center in  cm-1 
Helix peak 
center in  cm-1 
Leu 12 --- 1658 
Ile 13 1593 1659 
Val 14 1597 1659 
Val 17 1590 1658 
Leu 18 1591 1658 
Leu 19 1593 1659 
Phe 20 1596 1658 
Leu 21 1593 1658 
Ala 22 1595 1657 
Phe 23 1596 1659 
Val 24 1592 1659 
Val 25 1594 1657 
Phe 26 1583 1657 
Leu 27 1590 1659 
Leu 28 1592 1658 
Val 29 1597 1657 
Leu 31 1581 1658 
Ile 33 1597 1658 
Leu 34 1602 1659 
Average 1592 1658 
 
Table (4.4): Determination of the Position of the peak’s centers of the helix and the  
                     sites labeled with 13C=18O labels in D2O saturated samples (B). (residue No.  
                     12 has very weak label, and did not has peak for the labeled site)  
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Figure (4.6.a): Schematic diagram that shows the Position of peak’s centers of the helix  
                      and the site labeled with 13C=18O labels of the synthesized TMD of  
                      the SCoV E protein in ATR-FTIR spectrum in D2O saturated air  
                      sample table (4.3), the two arrows pointed at residues No.  26 and 31 Phe 
                      and  Leu  respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure (4.6.b): Schematic diagram that shows the Position of peak’s centers of the helix  
                      and the site labeled with 13C=18O labels of the synthesized TMD of  
                      the SCoV E protein in ATR-FTIR spectrum in D2O saturated air  
                      sample table (4.4), the two arrows pointed at residues No.  26 and 31 Phe 
                      and  Leu  respectively. 
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4.1.4. SARS CoV E protein has a unique transmembrane helical hairpin model with  
          two kinks within the lipid bilayer. 
    
      From the data obtained we may postulate two possibilities to describe the structure of 
the E protein: either as a single long transmembrane helix, or as two short helices forming a 
transmembrane helical hairpin. 
If it is a single helix, the hydrophobic stretch is too long relative to the bilayer thickness; on 
the other hand, the helical hairpin would have to be comprised of two very short helices in 
order to enable the 26 residues to traverse the membrane twice. Since the smallest possible 
loop (turn) is of five residues, each helix cannot contain more than 11–12 hydrophobic 
residues. This value is much smaller than the average of 21 residues per transmembrane 
helix. 
       In light of these results, one may consider possible molecular conformations. From 
previous FTIR results [25], we know that the protein helices are oriented perpendicular. 
From the density profiles of the iodinated protein, we know that the Phe-23 group is 
located at the hydrophilic/hydrophobic interface of the bilayer; at least at high hydration. 
This has led us to conclude that the SARS CoV E protein forms a small alpha-helical 
hairpin [25]. 
      The position of peak’s center for the helix and the site labeled with 13C=18O labels, for 
the synthesized TMD of the SCoV E protein, gave precious information about the structure 
of the TMD of the SCoV E protein. The center of the helix peaks position falls around the 
same region (1557-1559 cmˉ¹), and there were no difference between H2O and D2O 
saturated samples. this may indicate that all the synthesized samples of the   TMD of E 
protein of the SARS Coronavirus have the same helical structure, while in the sites labeled 
with 13C=18O labels, the peak’s centers falls around the same region (1590-1597 cmˉ¹ ) 
except for two residues (26 and 31). These two residues fall at a lower region than the rest 
of the residues (1581-1584 cmˉ¹) as shown in Figure (4.5, 4.6). The most likely explanation 
for this difference is the presence of kinks at these two residues. 
      It is important to indicate that these two kinks in the TMD of the SCoV E protein 
proposed for the first time in this work. And it is very important information that will help 
us in solving the secondary structure of the SARS E protein.  
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     These two  residues at position 26 and 31 falls in a lower region than the other residues. 
This may be due to the possibility that they are sites of a possible turns in TMD of the 
SCoV E protein, as shown in Figure (4.7). In residue No. 34 the position of the peak’s 
center of the labeled site falls at higher region than the other residue (1605 cmˉ¹). This  
maybe due to the closeness of the residue to the membrane surface.  
 
 
 
 
 
 
Figure (4.7): Diagram of the SCoV E protein hydrophobic region outlining the  
                       two points with expected turn. Hydrophobic amino acid residues are  
                       indicated by blue shading and hydrophilic residues are indicated by  
                       red shading, the bents site indicated by yellow shading Phe and Leu. 
 
 
By determining the area under the peaks of the site labeled with 13C=18O and the helix, 
we can calculate the dichroism ratio (R) for the labeled site and for the helix as shown in 
Table (4.7, 4.10) in both H2O and D2O saturated air samples. 
 
      The dichroism is equal to the area under the parallel peak (absorption obtained with the 
parallel polarized light)  of the helix or the labeled site║ (0°) divided by the area under the 
perpendicular peak (absorption obtained with the perpendicular polarized light) of the helix 
or the labeled site ┴ (90°). 
 
 
 
Equation (4.1): Dichroism which is defined as the ratio between the absorption of  
                           parallel and perpendicular polarized light. 
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Amino 
acid 
position 
Area under the labeled 
site peak 
       Area under helix peak     
. 
0°   90° 0°   90° 
Leu 12 -- -- 29.75573 7.288602 
Ile 13 0.127398 0.027571 18.43299 5.212362 
Val 14 0.131220 0.009990 11.43141 3.496748 
Val 17 0.272301 0.056114 13.37303 4.349404 
Leu 18 0.253021 0.055545 15.56820 4.305266 
Leu 19 0.197823 0.045196 16.43562 4.154623 
Phe 20 0.187070 0.030762 13.75650 3.387700 
Leu 21 0.179873 0.031975 10.66120 3.597235 
Ala 22 0.170353 0.034120 10.92228 3.038877 
Phe 23 0.215216 0.040581 15.73607 3.946313 
Val 24 0.259516 0.050628 18.60679 4.704165 
Val 25 0.208910 0.021742 15.43259 4.171179 
Phe 26 0.077874 0.067887 10.33257 2.507334 
Leu 27 0.116225 0.021275 12.79864 3.368135 
Leu 28 0.076212 0.012464 16.69371 4.057269 
Val 29 0.252402 0.022970 16.42986 4.129005 
Leu 31 0.114259 0.074300 14.81473 3.848605 
Ile 33 0.343566 0.052944 21.92058 5.801188 
Leu 34 0.354527 0.077233 20.63195 5.395729 
 
Table (4.5): Calculation of the area under the peaks of the helix and the sites labeled  
                     with 13C=18O labels in H2O saturated samples (A). 
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Amino 
acid 
position 
Area under the labeled 
site peak 
Area under Helix 
peak 
0°   90° 0°   90° 
Leu 12 -- -- 35.1510 7.6043 
Ile 13 0.1393 0.0178 16.5203 4.6403 
Val 14 0.0915 0.0133 5.3695 1.1499 
Val 17 0.2892 0.0403 13.1283 3.6783 
Leu 18 0.2598 0.0380 14.9701 4.0614 
Leu 19 0.1925 0.0506 16.3351 4.4060 
Phe 20 0.2010 0.0429 12.2920 2.9925 
Leu 21 0.1918 0.0296 9.86590 3.2673 
Ala 22 0.3538 0.0503 12.3788 3.6955 
Phe 23 0.2526 0.0551 15.0957 3.5085 
Val 24 0.2073 0.0381 11.1034 2.8155 
Val 25 0.3411 0.0421 17.9745 4.3144 
Phe 26 0.1035 0.0537 9.08420 2.3839 
Leu 27 0.1618 0.0332 14.4372 3.3576 
Leu 28 0.0763 0.0163 16.4590 4.0634 
Val 29 0.3044 0.0461 17.7977 4.0909 
Leu 31 0.1639 0.1221 16.3942 3.7881 
Ile 33 0.4073 0.0756 23.1024 5.5872 
Leu 34 0.3668 0.0928 22.7793 6.0316 
 
 
Table (4.6): Calculation of the area under the peaks of the helix and the sites labeled 
                     with 13C=18O labels in D2O saturated samples (A). 
 
 
  56 
 
Amino 
acid 
position 
H2O D2O 
R Helix R Site R Helix R Site 
Leu 12 4.1 ____ 4.6 ____ 
Ile 13 3.5 4.6 3.6 7.8 
Val 14 3.3 13.1 4.7 6.9 
Val 17 3.1 4.9 3.6 7.2 
Leu 18 3.6 4.6 3.7 6.8 
Leu 19 4.0 4.4 3.7 3.8 
Phe 20 4.1 6.1 4.1 4.7 
Leu 21 3.0 5.6 3.0 6.5 
Ala 22 3.6 5.0 3,4 7.0 
Phe 23 4.0 5.3 4.3 4.6 
Val 24 4.0 5.1 3.9 5.4 
Val 25 3.7 5.1 4.2 8.1 
Phe 26 4.1 1.1 3.8 1.9 
Leu 27 3.8 5.5 4.3 4.9 
Leu 28 4.1 6.1 4.1 4.7 
Val 29 4.0 11 4.4 6.6 
Leu 31 3.8 1.5 4.3 1.3 
Ile 33 3.8 6.5 4.1 5.4 
Leu 34 3.8 4.6 3.8 4.0 
 
Table (4.7): The dichoism ratio (R) for the site labeled with 13C=18O labels and for the  
                     helix in both H2O and D2O saturated air samples (A). 
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Amino 
acid 
position 
Area under the labeled 
site peak 
       Area under helix peak     
. 
0° 90° 0° 90° 
Leu 12 -- -- 13.46640 3.401761 
Ile 13 0.119680 0.028991 17.41518 5.078993 
Val 14 0.081400 0.008666 5.458285 1.420653 
Val 17 0.296281 0.053072 14.15910 4.548433 
Leu 18 0.236464 0.061364 14.86435 4.473001 
Leu 19 0.180174 0.039303 15.68670 3.670170 
Phe 20 0.156377 0.028095 12.39292 3.263825 
Leu 21 0.183251 0.029844 11.36454 3.359273 
Ala 22 0.157273 0.032392 10.07528 3.005962 
Phe 23 0.200536 0.036168 15.06762 3.862930 
Val 24 0.307432 0.063343 20.17228 5.399378 
Val 25 0.196163 0.020026 14.17995 4.040678 
Phe 26 0.072359 0.042802 10.08087 2.658089 
Leu 27 0.110958 0.022639 11.57420 2.916932 
Leu 28 0.082443 0.014867 18.79954 4.727484 
Val 29 0.270462 0.028811 16.08342 4.494517 
Leu 31 0.133665 0.073168 16.84216 4.292812 
Ile 33 0.352917 0.055369 22.65978 5.859195 
Leu 34 0.315501 0.074127 19.31885 4.514029 
 
Table (4.8): Calculation of the area under the peaks of the helix and the sites labeled 
                     with 13C=18O labels in H2O saturated samples (B). 
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Amino 
acid 
position 
Area under the labeled 
site peak 
   Area under helix peak     
.. 
0°   90° 0°   90° 
Leu 12 -- -- 12.2565 3.2619 
Ile 13 0.1440 0.0202 19.2936 4.7834 
Val 14 0.1646 0.0261 11.4232 3.2393 
Val 17 0.3465 0.0497 15.3726 4.0772 
Leu 18 0.2874 0.0425 16.1109 3.9108 
Leu 19 0.1866 0.0434 15.2248 3.6588 
Phe 20 0.1920 0.0460 12.6132 2.9447 
Leu 21 0.2073 0.0381 11.1034 2.8155 
Ala 22 0.1035 0.0152 8.8474 2.2738 
Phe 23 0.2397 0.0509 14.2460 3.6320 
Val 24 0.2103 0.0433 14.2886 3.5999 
Val 25 0.3388 0.0267 21.2583 5.0233 
Phe 26 0.0480 0.0357 10.2655 2.7062 
Leu 27 0.1317 0.0264 11.6150 2.9337 
Leu 28 0.1164 0.0138 18.6826 4.8121 
Val 29 0.2719 0.0289 16.3566 4.3694 
Leu 31 0.1359 0.0796 16.8152 4.2128 
Ile 33 0.4405 0.0858 24.2601 5.8277 
Leu 34 0.4447 0.1154 18.9193 5.3578 
 
Table (4.9): Calculation of the area under the peaks of the helix and the sites labeled 
                     with 13C=18O labels in D2O saturated samples (B). 
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Amino 
acid 
position 
H2O D2O 
R Helix R Site R Helix R Site 
Leu 12 4.0 ____ 3.8 ____ 
Ile 13 3.4 4.1 4.0 7.1 
Val 14 3.8 9.4 3.5 6.3 
Val 17 3.1 5.6 3.8 7.0 
Leu 18 3.3 3.9 4.1 6.8 
Leu 19 4.3 4.6 4.2 4.3 
Phe 20 3.8 5.6 4.3 4.2 
Leu 21 3.4 6.1 3.9 5.4 
Ala 22 3.4 4.9 3.9 6.8 
Phe 23 3.9 5.5 3.9 4.7 
Val 24 3.7 4.9 4.0 4.9 
Val 25 3.5 9.8 4.2 12.7 
Phe 26 3.8 1.7 3.8 1.3 
Leu 27 4.0 4.9 4.0 5.0 
Leu 28 4.0 5.5 3.9 8.4 
Val 29 3.6 9.4 3.7 9.4 
Leu 31 3.9 1.8 4.0 1.7 
Ile 33 3.9 6.4 4.2 5.1 
Leu 34 4.3 4.3 3.5 3.9 
 
Table (4.10): The dichoism ratio (R) for the site labeled with 13C=18O labels and for the  
                       helix in both H2O and D2O saturated air samples (B). 
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Figure (4.8.a): Schematic diagram shows the dichroism ratio (R) for the labeled site and 
                      for the helix in H2O saturated air samples table (4.7), the upper arrows       
                      pointed at residue No. 14,  25 and 29, the lower arrows pointed at residue No.   
                      26 and resedue No. 31. 
 
 
 
 
   
 
 
 
 
 
 
 
Figure (4.8.b): Schematic diagram shows the dichroism ratio (R) for the labeled site and 
                      for the helix in H2O saturated air samples (4.10), the upper arrows pointed  
                      at residue No. 14,  25 and 29, the lower arrows pointed at residue No. 26 
                      and 31.  
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4.1.5. Calculation of the dichroism (R) 
 
  The dichroism calculations confirm the hypothesis that the TMD of SARS CoV E protein 
may has two possible kinks as shown in Figure (4.8). These calculations of the dichroism 
for the residues No. 25 and 29 showed that there is an elevation in the dichroic values when 
compared to the other labeled sites dichroic values. While both residues No. 26 and 31 
have lower dichroic values than the others. All the sites labeled with 13C=18O labels have 
dichroic ratio between 3 to 7, which is lower than residues No. 25 and 29 dichroism. In the 
residues No. 26 and 31which have very low dichroic ratio (1.7-1.8), where the kinks are 
expected. The residues No. 25 and 29 that located before the residues No. 26 and 31 have a 
higher dichroic ratio (9-11) (pre-kink residues). In residue No. 30 it did not have label, but 
we can expect elevation in dichroic ratio too at this position, but it should be confirmed by 
future work. Residue No. 14 also showed elevation in the dichroic ratio, which also can be 
considered as pre-kink residue too. But we did not have residue No. 15 labeled , so we 
could not know the dichroic ratio here , it should be confirmed by future work too. 
All of this supports the idea of the presence of the kinks in those positions. 
 
 
4.1.6. Protein prediction programs 
 
 
4.1.6.1. The PSIPRED Protein Structure Prediction Server results 
 
 
 
Figure (4.9): The PSIPRED Protein Structure Prediction Server results showing  
                        the protein sequence prediction, the shaded area shows our  
                        synthesized peptide, where the helix starts  from the 12
th
 residue  
                        of the SARS E protein.  
                        Key, Conf: Confidence (0=low, 9=high), Pred: Predicted secondary   
                        structure, (H=helix, E=strand, C=coil), AA: Target sequence. 
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Figure (4.10): Schematic diagram for the PSIPRED Protein Structure Prediction  
                          Server results showing the protein sequence prediction, the shaded  
                          area shows our synthesized peptide, where the helix starts from  
                          the 12
th
 residue of the SARS E protein. Key, (H=helix, E=strand,  
                          C=coil). 
 
 
 
4.1.6.2. Predict Protein server results 
 
 
 
 
 
Figure (4.11): Predict Protein server results showing the protein sequence  
                         prediction, the shaded area shows our synthesized peptide, where  
                         the helix starts from the 6
th
 residue of the SARS E protein.  
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4.2. Discussion 
 
         The SCoV life cycle involves two distinct and important stages, the first is attachment 
and entry to target cells, and the second is budding and release from infected cells. In this 
research, we decided to study the SCoV E integral membrane protein, involved in these 
two stages. The E protein is an important factor in the budding process of the virus, which 
plays an important role in viral assembly along with the M protein. Where it causes major 
deformation of  the ER membrane. We decided to do further study on secondary structure 
of SCoV E protein and analyzing the structure of the protein and its affect on the lipid 
bilayer. 
 
     The evidence obtained in this research points to the fact that the SCoV E protein TMD 
forms an unusually short TM helical hairpin [25] with two kinks. And the secondary 
structure of the transmembrane domain is highly helical, and more than 80% of the protein 
is embedded in the lipid bilayer. 
 
     Using FTIR spectroscopy we analyzed the TMD of the SCoV E protein using 
synthesized peptide with labeled residues with 13C=18O which is capable of yielding 
accurate information about the position of each individual residue site in the TM helix 
bundle. We proposed a model structure for the protein that improves the earlier model 
proposed by Arbely E et al in 2004 [25], where they used unlabeled synthesized peptide, 
which gave them an approximate information about the position of each residue in the TM 
helix bundle because of the absence of the labeled residues with 13C=18O. 
     The entire hairpin structure containing the loop was subsequently subjected to energy 
minimization using global searching molecular dynamics simulations, their resulting model 
was a hairpin structure which contains a center of symmetry upon which it can be inverted 
as shown in Figure (4.13). 
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               Figure (4.13): Ribbon diagram of the structural model derived for the 
                                        transmembrane domain of SCoV E protein that proposed by  
                                        Arbely et al in 2004, which shows a hairpin structure    
                                       contains a center of symmetry upon which it can be inverted.  
 
         From the results of the position of the peak’s center (Table 4.1-4.4)  and the 
dichroism (Table 4.7, 4.10), we have found two points where we can expect turns in the 
transmembrane domain of SCoV E protein, these two residues present in the position 26 
and 31. It is important to indicate that this was reported for the first time in this work. We 
are proposing structural models for the transmembrane domain of SCoV E protein, which 
contain two kinks in the position 26 and 31 Phe and Leu respectively as shown in Figure 
4.14.  
     At residue No. 15 there is a possibility that we may have also a possible kink. The 
dichroism ratio of residue No. 14 was high just like the dichroism ratio of residues 25 and 
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29. these two residues followed with an expected turn. Since the residues No. 15 is not 
labeled with 13C=18O labels to confirm this result. This must be done.  We are planning in 
the   future to label residue No. 15 and 16 to confirm our results.  
There is other possibility that the dichroism ratio is high as a result of the weak absorbance 
intensity of the residue No. 14 spectrum, and this was due to the weak label, and to the low 
area under the site peaks. As shown in Figure 4.15  
    The schematic diagram of the structural models (Figure 4.14 and 4.15) designed for the 
transmembrane domain of SCoV E protein explaining models. Based on the results of the 
calculation for the dichroism and the peak’s center for the synthesized peptide labeled with 
13C=18O labels. It is important to indicate that the angels between the helical segments are 
not significant in those models. And all the schematic models were designed with respect to 
a previous study on the SCoV E protein that there is a helical hairpin [25]. 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4.14): Schematic diagram of the structural model derived for the 
                         transmembrane domain of SCoV E protein which contain two  
                         expected kinks in the position 26 and 31 Phe and Leu respectively. 
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Figure (4.15): Schematic diagram of the structural model derived for the 
                         transmembrane domain of SCoV E protein which contain three 
                         expected kinks in the position No. 14, 26 and 31 Asn,  Phe and Leu 
                         respectively.  
 
    In our model the shorter arm of the helical hairpin (C terminus) in our model (Figure4.14 
and 4.15) will deform the membrane while it will come close to this membrane, that is 
because it may expose the hydrophilic residues (non TMD residues) of the SCoV E protein 
[25].  
     The transmembrane hydrophobic segment of the SCoV E protein contains the shortest 
helical hairpin known. It contains 26 hydrophobic amino acid residues that traverse the 
lipid bilayer as two helices, and form a connecting two turn between the helices. Using 
negative staining electron microscopy Arbely showed the change in the structure and 
morphology of the lipid bilayer upon incorporating SCoV E protein transmembrane 
domain. While vesicles without protein (negative control) Figure (4.16 a) exhibited normal 
globular structure, SCoV E protein containing vesicles were markedly different Figure 
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(4.16 c), exhibiting extensive tubulation and deformation. Vesicles containing a positive 
control transmembrane protein, the MHC class II-associated invariant chain 
transmembrane domain were similar to vesicles without protein and did not exhibit any 
tubulation Figure (4.16 b).  
 
 
 
 
 
 
Figure (4.16): Negative staining electron micro-graphs of lipid DMPC vesicles  
                        (a), DMPC vesicles contain MHC class II-associated invariant  
                         chain transmembrane domain (b) and DMPC vesicles containing  
                       SCoV E protein transmembrane domain (c). All vesicles were  
                       extruded though a 200 nm filter.(Arbely E et al) 
 
      Protein structure prediction is a cornerstone of bioinformatics research. Membrane 
proteins require their own prediction methods due to their intrinsically different 
composition. A variety of tools exist for topology prediction of membrane proteins, many 
of them available on the Internet [61]. Membrane proteins are, in many respects, easier to 
investigate computationally than experimentally, due to the uniformity of their structure 
and interactions (e.g. consisting predominately of nearly parallel helices packed together). 
Using the prediction servers (which are helpful in giving a good idea about the secondary 
structure of transmembran domain of the protein) we predicted our SARS E protein. The 
PSIPRED Protein Structure Prediction Server results and predict protein server results 
Membrane Protein Secondary Structure Prediction Server results was almost the same in 
predicting the E protein, they all showed that the TM segment is a α-helix but the deference 
was only in the beginning of the α-helix segment, so it fully agree with our results that the 
TM domain of the E protein is α-helix, but it did not showed the tuirns that we proposed. 
      In a bioinformatics study for SARS E protein by Reddy et al [61], they showed also that 
the E protein have TM segment using different prediction servers and they made molecular 
a b c 
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modeling for the α-helix region using molecular dynamics simulation, which also agree 
with our results that the TM domain of the E protein is α-helix, as shown in Figure (4.17, 
4.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4.17): Secondary structure probabilities for SARS-CoV E protein from   
                        Protein  structure  prediction, the prediction was: α-helix (aa: 19-38)  
                        and b-sheets  (aa: 45-52 and 55-63).( Reddy et al) 
 
 
 
 
 
 
 
 
Figure (4.18): Simulated structure of a-helix (aa: 12-40) in SARS. Note that  
                        Amino acids: 19-38 is an α-helix. ( Reddy et al) 
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    Recently, Torres et al [62]. suggested a pentameric model for the transmembrane domain 
of the SCoV E protein. The possibility of forming a pentameric helical bundle was first 
suggested by Torres et al. after performing in vacuo molecular dynamics simulation of the 
putative TMD. The proposed model was further tested for evolutionary conservation, using 
13 coronavirus E protein homologous.  
  
     In our point of view there are two basic problems in the way this proposed pentameric 
model was calculated. First, the authors performed only global search molecular dynamics 
simulation of canonical (general, basic) helices, ignoring the possibility of a helical hairpin 
structure. In that case, the simulation will give rise only to helical bundle models composed 
of canonical _ helices. Second, an evolutionary conservation analysis requires some 
sequence similarity between the homologue proteins that are used for the analysis. 
Unfortunately, there is no sequence similarity between the TMD of the SCoV E protein and 
the TMDs of other coronaviruses’s E protein. Later, Torres et al. supported this model by 
SSID measurements of multiple labeled peptides in oriented lipid bilayers. We suggest that 
the authors are unaware of the possible implications that a modified peptide sequence 
might have on a structural study. First, the authors decided to use a shorter 5 residues 
peptide, which corresponds to residues 9–35 instead of residues 7–38. Second, the authors 
added two Lysine residues to both the amino and carboxy terminus of the peptide. In our 
opinion, these two changes have major impact on the structure of the TMD and its 
interactions with the membrane. One of the most prominent features of the SCoV E protein 
TMD is the unusually long hydrophobic stretch. 
 
     By using a shorter peptide, the authors obviously affected any characteristic of 
the peptide that this long hydrophobic stretch is responsible to. Furthermore, the 
addition of four positively charged Lysine residues to a peptide, which is only 27 
amino acid residues long, might have a major impact on its structure. Obviously, the 
positively charged residues may interact with the negatively charged lipid head 
groups. This interaction might overcome the favored interaction of the aromatic belt 
with the lipid-water interface. It should be stressed that at the amino terminus of this 
modified peptide; there are two Lysine residues instead of two Glutamate residues.  
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There is no doubt that addition of two negatively charged residues to two positively 
charged residues, will affect the overall structure of the peptide. 
 
     Not only that the pentameric model is based on misleading assumptions, recently 
published another work for the same author that contradicts this model and supports 
the helical hairpin model. Studied the membrane topology of the SCoV E protein by 
immunofluorescent staining and proteinase K protection assay. They found that both 
the amino and carboxy terminus of the SCoV E protein are exposed to the 
cytoplasmic side of the membrane. 
 
In this research work the obtained dichroic measurements of isotopically labeled TMDs  
which were performed by utilizing ATR-FTIR spectroscopy supposed to be used in a 
special computer program that can analyze the structure of regular (normal) helix, which 
give the measurements  (ω, β, Fa and Fb). Thos measurements can be later used in the 
global searching molecular dynamics simulations, which gave the exact structural model 
derived for the transmembrane domain of SCoV E protein. But in our research work the    
E protein that we studied has TM helix bundle with more than one turn. 
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